Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

Patients are eligible to be included in the study, if all the following inclusion criteria are met: - Patients with newly diagnosed diagnosed by tissue sample (biopsy-confirmed) epithelial ovarian cancer: - FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA) - FIGO stage III-IV of any histology - Women aged ≥18 years of age at the time of diagnosis - Patients intended for platinum-based chemotherapy treatment - Patients capable of giving signed willing to sign a consent form, which includes compliance with the requirements and restrictions listed in the willing to sign a consent form form (ICF) and in this protocol - Patients consent to provide archival tumor tissue sample Patients are ineligible to be included in the study, if any of the exclusion criteria are met: - Non-epithelial ovarian cancer, borderline tumors, or mucinous histology - Patients with FIGO stage I-II, BRCAwt ovarian cancer Always talk to your doctor about whether this trial is right for you.